Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 313

1.
2.

High-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: a prospective open study.

Wanchu A, Suryanaryana BS, Sharma S, Sharma A, Bambery P.

Int J Rheum Dis. 2009 Sep;12(3):239-42. doi: 10.1111/j.1756-185X.2009.01417.x.

PMID:
20374353
3.

Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis.

Seibold JR, Denton CP, Furst DE, Guillevin L, Rubin LJ, Wells A, Matucci Cerinic M, Riemekasten G, Emery P, Chadha-Boreham H, Charef P, Roux S, Black CM.

Arthritis Rheum. 2010 Jul;62(7):2101-8. doi: 10.1002/art.27466. Erratum in: Arthritis Rheum. 2010 Oct;62(10):3005.

4.

A long-term prospective randomized controlled study of non-specific interstitial pneumonia (NSIP) treatment in scleroderma.

Domiciano DS, Bonfá E, Borges CT, Kairalla RA, Capelozzi VL, Parra E, Christmann RB.

Clin Rheumatol. 2011 Feb;30(2):223-9. doi: 10.1007/s10067-010-1493-4.

PMID:
20544245
5.

Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): efficacy of maintenance immunosuppression in responders and non-responders.

Iudici M, Cuomo G, Vettori S, Bocchino M, Sanduzzi Zamparelli A, Cappabianca S, Valentini G.

Semin Arthritis Rheum. 2015 Feb;44(4):437-44. doi: 10.1016/j.semarthrit.2014.09.003.

PMID:
25282395
6.

Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study.

Bérezné A, Ranque B, Valeyre D, Brauner M, Allanore Y, Launay D, Le Guern V, Kahn JE, Couderc LJ, Constans J, Cohen P, Mahr A, Pagnoux C, Hachulla E, Kahan A, Cabane J, Guillevin L, Mouthon L.

J Rheumatol. 2008 Jun;35(6):1064-72.

PMID:
18464307
7.

Interstitial lung disease associated with systemic sclerosis: what is the evidence for efficacy of cyclophosphamide?

Bérezné A, Valeyre D, Ranque B, Guillevin L, Mouthon L.

Ann N Y Acad Sci. 2007 Sep;1110:271-84.

PMID:
17911442
8.

Efficacy of cyclophospamide in the treatment of interstitial lung disease associated with systemic sclerosis.

Espinosa G, Simeón CP, Plasín MÁ, Xaubet A, Muñoz X, Fonollosa V, Cervera R, Vilardell M.

Arch Bronconeumol. 2011 May;47(5):239-45. doi: 10.1016/j.arbres.2011.01.010. English, Spanish.

9.

A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide.

Sabnani I, Zucker MJ, Rosenstein ED, Baran DA, Arroyo LH, Tsang P, Zubair M, Rivera V.

Rheumatology (Oxford). 2009 Jan;48(1):49-52. doi: 10.1093/rheumatology/ken369.

PMID:
18815156
10.

Bosentan for severe pulmonary arterial hypertension related to systemic sclerosis with interstitial lung disease.

Ahmadi-Simab K, Hellmich B, Gross WL.

Eur J Clin Invest. 2006 Sep;36 Suppl 3:44-8.

PMID:
16919010
11.

Long-term follow-up of patients with scleroderma interstitial lung disease treated with intravenous cyclophosphamide pulse therapy: a single-center experience.

Balbir-Gurman A, Yigla M, Guralnik L, Hardak E, Solomonov A, Rozin AP, Toledano K, Dagan A, Bishara R, Markovits D, Nahir MA, Braun-Moscovici Y.

Isr Med Assoc J. 2015 Mar;17(3):150-6.

12.

Mycophenolate versus cyclophosphamide for progressive interstitial lung disease associated with systemic sclerosis: a 2-year case control study.

Panopoulos ST, Bournia VK, Trakada G, Giavri I, Kostopoulos C, Sfikakis PP.

Lung. 2013 Oct;191(5):483-9. doi: 10.1007/s00408-013-9499-8.

PMID:
23925736
13.

Oral cyclophosphamide improves pulmonary function in scleroderma patients with fibrosing alveolitis: experience in one centre.

Beretta L, Caronni M, Raimondi M, Ponti A, Viscuso T, Origgi L, Scorza R.

Clin Rheumatol. 2007 Feb;26(2):168-72.

PMID:
16614793
14.

A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.

Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, Roberts C, Desai S, Herrick AL, McHugh NJ, Foley NM, Pearson SB, Emery P, Veale DJ, Denton CP, Wells AU, Black CM, du Bois RM.

Arthritis Rheum. 2006 Dec;54(12):3962-70.

15.

Interstitial lung disease in systemic sclerosis.

Bussone G, Mouthon L.

Autoimmun Rev. 2011 Mar;10(5):248-55. doi: 10.1016/j.autrev.2010.09.012. Review.

PMID:
20863911
16.

Management of interstitial lung disease in systemic sclerosis: lessons from SLS and FAST.

Fathi N, Furst DE, Clements PJ.

Curr Rheumatol Rep. 2007 May;9(2):144-50.

PMID:
17502045
17.

Bosentan in systemic sclerosis.

Heresi GA, Minai OA.

Drugs Today (Barc). 2008 Jun;44(6):415-28. doi: 10.1358/dot.2008.44.6.1220138. Review.

PMID:
18596996
18.

Esophageal involvement and pulmonary manifestations in systemic sclerosis.

Marie I, Dominique S, Levesque H, Ducrotté P, Denis P, Hellot MF, Courtois H.

Arthritis Rheum. 2001 Aug;45(4):346-54.

19.

Supplemental Content

Support Center